Status:

COMPLETED

Efficacy Study of Everolimus on Renal Function in Heart Transplant Recipients With Established Chronic Renal Failure

Lead Sponsor:

Hospices Civils de Lyon

Conditions:

Cardiac Transplantation

Chronic Renal Insufficiency

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

After transplantation, renal impairment, incidence and progression of atherosclerosis lead to modification of immunosuppressive regimens, as switch, reduction or discontinuation of CNI and/or introduc...

Eligibility Criteria

Inclusion

  • Male or female cardiac recipients over 18 years old
  • First or second heart transplant, more than one year following surgery
  • Patients with renal failure assessed by cGFR 30 to 60 ml/min/1,73m² calculated by MDRD4 formula
  • Patients volunteer to participate in the study, with a written informed consent signed
  • Affiliation to a national health insurance program

Exclusion

  • Current CNI-free immunosuppressive regimen
  • Patients currently or previously treated with a mTOR inhibitor any time prior randomization
  • Patients who are recipients for a multiple solid organ transplant
  • Treated acute rejection episode within three months prior randomization
  • Congestive heart failure (NYHA class III or IV) and/or VEF \< 30 % and/or patient waiting for a re-transplantation
  • Scheduled surgical intervention
  • Platelet count \< 50 G/l
  • Severe hepatic insufficiency (SGPT and/or SGOT \> 3N)
  • Major lipidic profile abnormalities (total cholesterol \> 3g/l and/or TG \> 5g/l)
  • Proteinuria/creatinuria \> 0,08 g/mmol
  • Severe renal failure attested by cGFR \< 30 ml/min/1.73m² (MDRD4)
  • History of Hypersensitivity to everolimus, sirolimus or excipients
  • History of Hypersensitivity to macrolides
  • Pregnancy and breast feeding
  • Childbearing age women without efficient contraception
  • Law protected patients
  • Patients in emergency unable to express their consent
  • History of Hypersensitivity to cyclosporine or St-John's wort, stiripentol, bosentan, rosuvastatin
  • History of Hypersensitivity to tacrolimus, macrolides or excipients
  • History of Hypersensitivity to azathioprine
  • History of Hypersensitivity to mycophénolate mofetil or excipients

Key Trial Info

Start Date :

September 16 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 17 2014

Estimated Enrollment :

120 Patients enrolled

Trial Details

Trial ID

NCT00716573

Start Date

September 16 2008

End Date

April 17 2014

Last Update

June 20 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hospices Civils de Lyon

Lyon, France